Affitech A/S
The final part of the share capital reduction adopted at the ordinary general meeting on 27th April, 2012 is completed and has been registered with the Danish Business Authority – updated articles of association

Affitech A/S 

08.06.2012 10:24

Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Release no. 16/2012

Copenhagen and Oslo, 8th June, 2012, 2012-06-08 10:24 CEST (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced
that the Company today has completed the reduction of the Company's share
capital by DKK 82,912,661.63, nominal value, from DKK 87,789,877.02, nominal
value, to DKK 4,877,215.39, nominal value. 



The capital reduction was decided at the company's general meeting on 27th
April, 2012. The Company's creditors were subsequently (on 10th May 2012)
invited to prove their claims to the company within four weeks. No creditors
have proven any claim within these four weeks. 



The capital reduction has been allocated to a separate reserve, pursuant to
section 188(1)(3) of the Danish Companies Act. 



The capital reduction has been carried out by a reduction of the denomination
of all of the shares issued by the Company, as the denomination of all issued
shares are reduced from DKK 0.18, nominal value, to DKK 0,01, nominal value. 



Affitech A/S' articles of association have been revised as a consequence of the
capital reduction. The new articles of association are attached hereto and will
also be available on the company's website as from today. 





About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The Company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS(TM) (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules. Affitech co-develops its two lead antibody drug
programs AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. The
Company's initial focus is on rapid and cost effective development by
partnering clinical trials in emerging markets. Further information is
available at www.affitech.com. 



Disclaimer
This announcement may contain forward-looking statements including statements
about Affitech's expectations of the progression of its pipeline including the
timing for commencement and completion of clinical trials and with respect to
cash burn guidance. Such statements are based on Management's current
expectations and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those described in the
forward-looking statements. Affitech cautions investors that there can be no
assurance that actual results or business conditions will not differ materially
from those projected or suggested in such forward-looking statements as a
result of various factors, including, but not limited to, the following: risks
associated with technological development, the risk that research & development
will not yield new products that achieve commercial success, the impact of
competition, the ability to transact viable and profitable commercial deals,
the risk of non-approval of patents not yet granted, and difficulties of
obtaining relevant governmental approvals for new products. No expressed or
implied representations or warranties are given concerning Affitech A/S or the
accuracy or completeness of the information provided herein, and no claims
shall be made by the recipient of this news release by virtue of the
information contained herein. 


         Contact:
         
         Randi Krogsgaard, Director IR & Corporate Communications
         
         Tel # +45 2320 1001, e-mail: ir@affitech.com
News Source: NASDAQ OMX



08.06.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Affitech A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0015966592
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------